What STC Biologics does

STC Biologics, Inc. is a privately held boutique contract development and manufacturing organization (CDMO) headquartered in Newton, Massachusetts, providing integrated Chemistry, Manufacturing, and Controls (CMC) services for biologics drug development. Founded in 2009 by Dr. Magdalena Leszczyniecka, the company serves biopharmaceutical clients seeking to advance monoclonal antibodies (MAbs), biosimilars, and novel biologics (including Fc fusion proteins, antibody single chains, and antibody-targeted liposomal formulations) from discovery through commercialization. The client base spans biotech companies facing complex process and analytical challenges, timeline pressure, or template process failures, with particular focus on biosimilar developers targeting European and US regulatory pathways.

STC's core offering is the Speed-To-Clinic Platform™, an integrated CMC program that takes MAbs from royalty-free cell line development directly through cGMP manufacturing to released drug substance within 12 months. The underlying technology platform includes mammalian cell culture capabilities across CHO, NS0, Sp2/0, and PER.C6® lines, proprietary biosimilar clone-screening methods that reduce candidate evaluation from approximately 1,000 clones to 2 best producers by decoupling productivity from critical quality attributes such as glycosylation, and high-resolution mass spectrometry using a Q-Exactive Orbitrap instrument capable of 2-3 Da accuracy on 150 kDa antibodies and semi-quantitative glycovariant analysis. The scientific staff is deliberately cross-trained across biology, process development, analytics, formulation, and regulatory sciences to enable an integrated biology-CMC approach. STC holds three granted patents covering methods to achieve fingerprint-like biosimilar similarity and operates three GMP clean rooms with manufacturing scale up to 2x1000L bioreactors. Management team credentials include 8+ BLAs, 20+ INDs, 20+ comparability protocols, and lifecycle experience on 5 approved biologics (Replagal, Elaprase, Dynepo, VIPRIV, Firazyr) drawn from prior roles at Genentech, Novartis, Shire, EMD Serono, Lonza, Alexion, and Merrimack.

Revenue is generated primarily through project-based contracts for CMC consulting and full-service development programs, supplemented by managed services for GMP release and stability testing and a licensing/royalty stream tied to proprietary biosimilar assets (notably STC101, which was advanced from concept to clinical development in Europe under EMA guidance). Pricing is determined per-project based on scope, materials, timelines, and resources, and not publicly disclosed. STC employs a direct enterprise sales motion targeting biotech and pharma management teams, with no channel or reseller distribution model. Geographic focus spans North America and Europe, and marketing relies on industry conferences (BIO2024, PEGS, ISPE), scientific publications, and the CEO's advisory roles with sectoral investment firms.

Name

STC Biologics

Legal name

STC Biologics, Inc.

Website

https://stcbiologics.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

STC Biologics is a privately held boutique CDMO founded in 2009 in Newton, Massachusetts that provides integrated CMC development, GMP manufacturing, and regulatory services for monoclonal antibodies, biosimilars, and novel biologics to biopharmaceutical clients.

Ownership category

akta.pro rank

Product category

Biologics Contract Development & Manufacturing (CDMO)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Biologics CDMO services
• Cell line development
• Process development
• Biosimilar development
• GMP biologics manufacturing

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: Full CMC services including CMC consulting, cell line development, process development, analytical development, formulation development, GMP production, and regulatory strategy. Revenue generated through project-based contracts with biotech and pharma partners seeking to advance biologics from preclinical through commercialization.
2. GMP Release and Stability Testing: Quality Systems for GMP release and stability testing services including compendial tests, quantitative peptide map, electrophoretic, HPLC, immunoassays, qPCR-based purity analysis, bioactivity and cell-based potency assays.
3. Proprietary Biosimilar Development: Internal development of biosimilar products, including STC101 which was advanced from concept to clinical development in Europe under EMA guidance.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

STC Biologics is a boutique turn-key Contract Development and Manufacturing Organization (CDMO) that delivers integrated CMC services for monoclonal antibodies, biosimilars, and novel biologics. Its flagship offering is the Speed-To-Clinic Platform™, which advances MAbs from royalty-free cell line development through cGMP manufacturing to released drug substance within 12 months, supported by cell line development, process development, analytical development, formulation development, GMP production, and regulatory strategy services for biotech and pharmaceutical clients.

Product overview

STC Biologics is a boutique turn-key CDMO offering a unified portfolio of biologics development services rather than a single software product. The core offering is the Speed-To-Clinic Platform™ for MAbs, supplemented by their in-house biosimilar product STC101. The service portfolio includes integrated CMC services spanning cell line development (CHO, NS0, Sp2/0, PER.C6®), process development, analytical development, mass spectrometry, bioanalytical/bioassay services, formulation development, GMP production, and regulatory strategy—all designed to advance biologic products from discovery through commercialization. The services are offered both as integrated packages through the Speed-To-Clinic Platform™ and as individual consulting engagements.

Differentiator

Problem solved

Functional benefit

Brands

• Speed-To-Clinic Platform™: A platform for MAbs starting from royalty free Cell Line Development directly to cGMP Manufacturing and released Drug Substance within only 12 months

Products and services

• Speed-To-Clinic Platform™ Integrated CMC development platform for MAbs that takes royalty-free cell line development through cGMP manufacturing to released drug substance within 12 months, designed to compress timelines to clinic for biotech and pharma partners developing monoclonal antibodies.
• Cell Line Development Cell line development services for CHO, NS0, Sp2/0, and PER.C6® human cell lines including vector construction, transfection, stable clone selection, and research and GMP cell bank development for biologics manufacturers.
• Process Development Upstream and downstream process development services covering media/feed optimization, bioreactor scale-up from 1L to 50L, purification process development, viral inactivation and filtration, and UF/DF operations for biologics manufacturing.
• Analytical Development & Qualification Development and qualification of release and stability assays including HPLC, electrophoretic assays, immunoassays (ELISA), cell-based bioassays, and regulatory section authoring for biotherapeutic characterization.
• Mass Spectrometry Services High-resolution mass spectrometry services on a Q-Exactive Orbitrap platform providing intact mass analysis (2-3 Da accuracy on 150 kDa antibodies), deamidation analysis, semi-quantitative glycovariant distribution, peptide map MS/MS, and Target ID/HCP analysis.
• Bioanalytical Assays (PK & Immunogenicity) Bioanalytical services measuring biologic product concentration in serum and blood, including PK assay development and testing, immunogenicity assay development and testing, and anti-drug antibody assay development for clinical and preclinical programs.
• Bioassays Custom biological assay development examining the mechanism of action of biologic products, including antigen/receptor binding, Fc receptor panels, cellular responses (ADCC, CDC), signal transduction, and gene transcription reporter assays.
• Formulation Development Preformulation studies, formulation development (liquid or lyophilized products, nanoparticles, liposomes), stability studies, forced degradation studies, and characterization of degradation pathways for biologic formulations.
• GMP Production Mammalian GMP manufacturing services from three clean room suites (3.5L to 2x1000L scale) covering Master Cell Banking, small to large scale production, and GMP buffer and formulation preparation for biotherapeutics.
• Product & Impurity Characterization / Comparability Comprehensive structural, glycosylation, impurity, and biological activity characterization using orthogonal analytical tools (MS/MS, HPLC, electrophoresis, ELISA, and cell-based bioassays) with comparability strategy development per ICH Q5E.
• Scale Down Process Characterization Process characterization services analyzing how process variables affect product quality, including study of media batches, temperature, dissolved oxygen, pH, and feed parameters to ensure successful scale-up and transfer of bioprocesses.
• Release Testing & Stability Programs GMP release testing and stability program services for biotherapeutics, including drug substance and drug product stability testing under real-time, accelerated, and stress conditions.
• Technology Transfer Process and analytical method transfer services including preparation of process development reports, test methods, assay qualification reports, and troubleshooting support for US and EU manufacturing sites.
• Regulatory Strategy & CMC Section Authoring Regulatory strategy and CMC section authoring services including phase-appropriate CMC strategy aligned with ICH guidelines, gap analysis, IND/BLA/NDA authoring in CTD format, comparability strategy, and specifications strategy for biologic submissions.
• CMC Consulting Phase-appropriate CMC strategy consulting covering process development, analytical development, formulation development, comparability strategy, specifications development, stability program design, and CMO management for biologic drug development programs.
• STC101 (Biosimilar Product) In-house biosimilar monoclonal antibody product developed by STC from concept to clinical development in Europe under EMA guidance, representing the company's first biosimilar asset.

Quantifiable outcome

• 12-month timeline from royalty-free cell line to released drug substance
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered minor.

• Boston UniversityminorStrategic or Co-development PartnerOngoing collaboration between Boston University and STC Biologics on B cell response research in Tuberculosis. Work led by Dr. Lisa Ganley-Leal (Director of Infectious Diseases) and Dr. Thomas Schneider (Director of Biology) resulting in publication in Global Vaccine and Immunology Journal.
• CytoviaminorOthersFeatured partner in STC Biologics' partnership section indicating potential collaboration interest. No specific partnership details provided.

Scale indicators10 records

Recent moves8 records

Expansion highlights7 records

Market position

Strengths4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/stcbiologics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about STC Biologics